文献速递心力衰竭与心肌病心律失常

克隆性造血在扩张型心肌病发病机制中的新兴作用

The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy.
PubMed 文献 · Eur Heart J · 2024-01-01

新型DNA测序技术可识别造血干细胞小克隆中的体细胞突变,驱动基因突变导致克隆性造血(CH),CH已成为心血管疾病(如心力衰竭)的新风险因素。扩张型心肌病(DCM)是非缺血性心力衰竭的一种,病因异质,初步证据表明CH在DCM病程中起重要作用,并与炎症、化疗、房颤等多种病因强烈相关。CH诱导的心肌炎症可能是易感心脏(如存在遗传变异、环境触发因素和合并症时)发生DCM的重要触发因素,未来需标准化报告方法和结果以推动领域发展。

要点

  • 克隆性造血(CH)是心血管疾病包括心力衰竭的新兴风险因素。
  • CH与扩张型心肌病(DCM)的多种病因(炎症、化疗、房颤)强烈相关。
  • CH驱动基因突变可激活炎症小体通路,为抗炎治疗提供潜在靶点。

核心结论

  • 克隆性造血(CH)在扩张型心肌病(DCM)发病机制中可能起重要作用,并与多种DCM病因强烈相关。

研究设计与样本

  • 本文为综述,基于文献总结CH在DCM发病机制中的新兴作用,未报告原始研究样本量。

主要发现

  • CH与DCM的多种病因(如炎症、化疗和房颤)存在强烈关联。
  • CH诱导的心肌炎症可能是易感心脏(如存在遗传变异、环境触发因素和合并症时)发生DCM的重要触发因素。
  • CH驱动基因突变可激活炎症小体通路,为特异性抗炎治疗提供指导。

临床怎么用

  • 在DCM患者中准确测量CH可能为特异性(抗炎)治疗提供指导。
  • 未来研究需标准化报告CH的方法和结果,以便结果可合并和比较。

局限性

  • 本文为综述,未报告原始研究数据,结论基于现有证据的总结。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The increased sensitivity of novel DNA sequencing techniques has made it possible to identify somatic mutations in small circulating clones of haematopoietic stem cells. When the mutation affects a 'driver' gene, the mutant clone gains a competitive advantage and has the potential to expand over time, a phenomenon referred to as clonal haematopoiesis (CH), which is emerging as a new risk factor for various non-haematological conditions, most notably cardiovascular disease (e.g. heart failure). Dilated cardiomyopathy (DCM) is a form of non-ischaemic heart failure that is characterized by a heterogeneous aetiology. The first evidence is arising that CH plays an important role in the disease course in patients with DCM, and a strong association of CH with multiple aetiologies of DCM has been described (e.g. inflammation, chemotherapy, and atrial fibrillation). The myocardial inflammation induced by CH may be an important trigger for DCM development for an already susceptible heart, e.g. in the presence of genetic variants, environmental triggers, and comorbidities. Studies investigating the role of CH in the pathogenesis of DCM are expected to increase rapidly. To move the field forward, it will be important to report the methodology and results in a standardized manner, so results can be combined and compared. The accurate measurement of CH in patients with DCM can provide guidance of specific (anti-inflammatory) therapies, as mutations in the CH driver genes prime the inflammasome pathway.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Verdonschot JAJ, Fuster JJ, Walsh K, et al. The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy. Eur Heart J. 2024. PMID: 39417710. doi:10.1093/eurheartj/ehae682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。